Literature DB >> 32391613

Targeting telomerase for its advent in cancer therapeutics.

Shalini Bajaj1, Maushmi S Kumar1, G J Peters2, Y C Mayur1.   

Abstract

Telomerase has emerged as an important primary target in anticancer therapy. It is a distinctive reverse transcriptase enzyme, which extends the length of telomere at the 3' chromosomal end, and uses telomerase reverse transcriptase (TERT) and telomerase RNA template-containing domains. Telomerase has a vital role and is a contributing factor in human health, mainly affecting cell aging and cell proliferation. Due to its unique feature, it ensures unrestricted cell proliferation in malignancy and plays a major role in cancer disease. The development of telomerase inhibitors with increased specificity and better pharmacokinetics is being considered to design and develop newer potent anticancer agents. Use of natural and synthetic compounds for the inhibition of telomerase activity can lead to an opening of new vistas in cancer treatment. This review details about the telomerase biochemistry, use of natural and synthetic compounds; vaccines and oncolytic virus in therapy that suppress the telomerase activity. We have discussed structure-activity relationships of various natural and synthetic telomerase inhibitors to help medicinal chemists and chemical biology researchers with a ready reference and updated status of their clinical trials. Suppression of human TERT (hTERT) activity through inhibition of hTERT promoter is an important approach for telomerase inhibition.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  cancer; hTERC; hTERT; telomerase; telomerase inhibitors; telomere

Year:  2020        PMID: 32391613     DOI: 10.1002/med.21674

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  7 in total

1.  Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

Authors:  Teng He; Zhixing Hao; Mingjie Lin; Zhongwei Xin; Yongyuan Chen; Wei Ouyang; Qi Yang; Xiaoke Chen; Hui Zhou; Wanying Zhang; Pin Wu; Feng Xu
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

2.  MAPK/ERK-CBP-RFPL-3 Mediates Adipose-Derived Stem Cell-Induced Tumor Growth in Breast Cancer Cells by Activating Telomerase Reverse Transcriptase Expression.

Authors:  Wenjie Li; Cheng Qian; Fei Ma; Meng Liu; Xiaojun Sun; Xu Liu; Chunxiao Liu; Zhenghua Chen; Weichang Ma; Jian Liu; Haiqian Xu; Zhenlin Yang
Journal:  Stem Cells Int       Date:  2022-06-07       Impact factor: 5.131

3.  Targeting visualization of malignant tumor based on the alteration of DWI signal generated by hTERT promoter-driven AQP1 overexpression.

Authors:  Liang Zhang; Mingfu Gong; Sheng Lei; Chun Cui; Yun Liu; Shilin Xiao; Xun Kang; Tao Sun; Zhongsheng Xu; Chunyu Zhou; Si Zhang; Dong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-19       Impact factor: 10.057

Review 4.  Shelterin complex gene: Prognosis and therapeutic vulnerability in cancer.

Authors:  Vikas Kumar Bhari; Durgesh Kumar; Surendra Kumar; Rajeev Mishra
Journal:  Biochem Biophys Rep       Date:  2021-02-02

Review 5.  Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.

Authors:  Congxin Dai; Bowen Sun; Shusen Guan; Wei Wang; Honggang Liu; Yong Li; Jialiang Zhang; Jun Kang
Journal:  BMC Endocr Disord       Date:  2021-10-29       Impact factor: 2.763

6.  New Genetic Bomb Trigger: Design, Synthesis, Molecular Dynamics Simulation, and Biological Evaluation of Novel BIBR1532-Related Analogs Targeting Telomerase against Non-Small Cell Lung Cancer.

Authors:  Haytham O Tawfik; Anwar A El-Hamaky; Eman A El-Bastawissy; Kirill A Shcherbakov; Alexander V Veselovsky; Yulia A Gladilina; Dmitry D Zhdanov; Mervat H El-Hamamsy
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14

Review 7.  Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes.

Authors:  Anna A Plyasova; Dmitry D Zhdanov
Journal:  Biomedicines       Date:  2021-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.